Always a pleasure to catch-up with Editorial Board member, Bengt Winblad (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden), who chatted with us on several topics including the MOPEAD initiative. MOPEAD (Models of Patient Engagement for Alzheimer’s disease), aims to deliver a step-change in AD patient engagement strategies and a paradigm shift from late-stage diagnosis to early-stage diagnosis. It strives to improve the identification of subjects with mild cognitive impairment at an early stage. For more information visit: https://www.mopead.eu/
Questions
1. Could you give us a brief overview of the aims and design of the Models Of Patient Engagement for Alzheimer’s Disease (MOPEAD) project? (0:05)
2. What have been the major findings of the project to date? (4:03)
Also see linked videos with Bengt Winblad:
Emerging therapeutic targets for Alzheimer’s disease
Targeting Beta-amyloid for the Treatment of Early Alzheimer’s
Swedish Geriatric Neurologist Perspective on COVID-19
Speaker disclosure: Bengt Winblad has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
